These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

537 related items for PubMed ID: 19747143

  • 21. Novel β-lactam-β-lactamase inhibitor combinations: expectations for the treatment of carbapenem-resistant Gram-negative pathogens.
    Karaiskos I, Galani I, Souli M, Giamarellou H.
    Expert Opin Drug Metab Toxicol; 2019 Feb; 15(2):133-149. PubMed ID: 30626244
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Beta-lactamases and beta-lactamase inhibitors.
    Williams JD.
    Int J Antimicrob Agents; 1999 Aug; 12 Suppl 1():S3-7; discussion S26-7. PubMed ID: 10526867
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Beta-lactamase-mediated resistance and opportunities for its control.
    Livermore DM.
    J Antimicrob Chemother; 1998 Jun; 41 Suppl D():25-41. PubMed ID: 9688449
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Designing Inhibitors of β-Lactamase Enzymes to Overcome Carbapenem Resistance in Gram-Negative Bacteria.
    Davies DT, Everett M.
    Acc Chem Res; 2021 May 04; 54(9):2055-2064. PubMed ID: 33788541
    [Abstract] [Full Text] [Related]

  • 29. Crystal structure of the IMP-1 metallo beta-lactamase from Pseudomonas aeruginosa and its complex with a mercaptocarboxylate inhibitor: binding determinants of a potent, broad-spectrum inhibitor.
    Concha NO, Janson CA, Rowling P, Pearson S, Cheever CA, Clarke BP, Lewis C, Galleni M, Frère JM, Payne DJ, Bateson JH, Abdel-Meguid SS.
    Biochemistry; 2000 Apr 18; 39(15):4288-98. PubMed ID: 10757977
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. [Beta-lactamases and their role in resistance. PART 2: beta-lactamases in 21st century].
    Bedenić B.
    Lijec Vjesn; 2005 Apr 18; 127(1-2):12-21. PubMed ID: 16145868
    [Abstract] [Full Text] [Related]

  • 37. WCK 5222 (cefepime/zidebactam) antimicrobial activity tested against Gram-negative organisms producing clinically relevant β-lactamases.
    Sader HS, Rhomberg PR, Flamm RK, Jones RN, Castanheira M.
    J Antimicrob Chemother; 2017 Jun 01; 72(6):1696-1703. PubMed ID: 28333332
    [Abstract] [Full Text] [Related]

  • 38. β-lactam antibiotics: An overview from a medicinal chemistry perspective.
    Lima LM, Silva BNMD, Barbosa G, Barreiro EJ.
    Eur J Med Chem; 2020 Dec 15; 208():112829. PubMed ID: 33002736
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Beta-lactamase inhibitors: evolving compounds for evolving resistance targets.
    Georgopapadakou NH.
    Expert Opin Investig Drugs; 2004 Oct 15; 13(10):1307-18. PubMed ID: 15461559
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 27.